Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS (ALXN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/15/2018 10/16/2018 10/17/2018 10/18/2018 10/19/2018 Date
121.49(c) 127.7(c) 128.94(c) 126.56(c) 125.89(c) Last
1 059 970 1 379 552 934 223 891 174 1 156 042 Volume
-0.37% +5.11% +0.97% -1.85% -0.53% Change
More quotes
Financials (USD)
Sales 2018 4 041 M
EBIT 2018 2 021 M
Net income 2018 189 M
Debt 2018 1 532 M
Yield 2018 -
Sales 2019 4 723 M
EBIT 2019 2 405 M
Net income 2019 1 306 M
Finance 2019 2 345 M
Yield 2019 -
P/E ratio 2018 66,08
P/E ratio 2019 20,58
EV / Sales2018 7,32x
EV / Sales2019 5,44x
Capitalization 28 056 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded... 
Sector
Pharmaceuticals
Calendar
10/24Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
10/10ALEXION PHARMACEUTICALS : to Report Third Quarter 2018 Results on Wednesday, Oct..
AQ
10/04ALEXION PHARMACEUTICALS : to Report Third Quarter 2018 Results on Wednesday, Oct..
BU
10/01ALEXION PHARMACEUTICALS : to Acquire Syntimmune
AQ
10/01ALEXION PHARMACEUTICALS : to Present at the Leerink Partners Roundtable Series, ..
AQ
10/01Blueprint Medicines unveils preclinical data for rare bone disease program
AQ
09/27ALEXION PHARMACEUTICALS : Correction to Alexion to Buy Syntimmune Stories on Sep..
DJ
09/26ALEXION PHARMACEUTICALS : Announces Successful Phase 3 PREVENT Study of Soliris ..
AQ
09/26ALEXION PHARMACEUTICALS : to Buy Syntimmune for Up to $1.2 Billion -- Update
DJ
09/26MARKETS RIGHT NOW : Stocks open higher on Wall Street
AQ
09/26ALEXION PHARMACEUTICALS : to Acquire Syntimmune
BU
More news
Sector news : Biopharmaceuticals
10/19FDA Approves Asthma Indication for Regeneron and Sanofi's Dupixent
DJ
10/19ABBVIE : CFO Chase to retire by mid-year 2019
RE
10/19MYLAN : Launches Hulio, a Biosimilar to Humira, in Europe
DJ
10/19FDA Approves Label Update for Genentech's Rituxan
DJ
10/19ABBVIE : Chief Financial Officer Chase to Retire; Michael Takes Post
DJ
More sector news : Biopharmaceuticals
Latest Tweets
10/20Zacks: Brokerages Expect Alexion Pharmaceuticals, Inc. $ALXN Will Post Quarte.. 
10/20Alexion Pharmaceuticals, Inc. $ALXN Given Consensus Rating of “Buy” by Broker.. 
10/18Credit Suisse Group Analysts Give Alexion Pharmaceuticals $ALXN a $156.00 Pri.. 
10/18Piper Jaffray Companies Raises Alexion Pharmaceuticals Q3 2018 Earnings Estim.. 
10/18Alexion Pharmaceuticals, Inc. $ALXN to Post Q3 2018 Earnings of $1.60 Per Sha.. 
More tweets
Qtime:158
News from SeekingAlpha
10/18MARKER THERAPEUTICS : A Safer And Potentially More Effective CAR-T Alternative 
10/09Invesco S&P 500 Equal Weight ETF (RSP) September Summary 
10/05The Biotech Conundrum 
10/03Healthcare And Biotechnology Dashboard - Update 
09/27Best And Worst-Performing Stocks In The S&P 500 Over The Last 20 Years And Ho.. 
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 163 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP & Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS1.59%28 205
BIOGEN3.09%66 506
CSL LIMITED33.70%60 790
BIOMARIN PHARMACEUTICAL11.60%18 437
GRIFOLS-9.36%16 648
WUXI BIOLOGICS CAYMAN INC--.--%9 830